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Abstract
Introduction: Gamma-hydroxybutyric-acid is a potentially addictive drug known for its use in
“rave” parties. Users have described heightened sexual drive, sensuality and emotional warmth. Its
euphoric, sedative and anxiolytic-like properties are also sought by frequent users. Abrupt gamma-
hydroxybutyric-acid withdrawal can rapidly cause tremor, autonomic dysfunction and anxiety, and
may later culminate in severe confusion, delirium, auditory, visual or tactile hallucinations, or even
death.
Case presentation: A 23-year-old woman presented to the emergency room with paranoid
delusions and auditory hallucinations. Her psychiatric history included two brief psychotic episodes
induced by amphetamines and marijuana. In the last six months, she had demonstrated bizarre
behaviour, had been more isolated and apathetic, and unable to take care of daily chores. The
patient reported occasional use of gamma-hydroxybutyric-acid, but her initial accounts of drug use
were contradictory. Since the toxicology urine screen was negative, a schizophrenic disorder was
initially suspected and an antipsychotic medication was prescribed. A few hours after her
admission, signs of autonomic dysfunction (tachycardia and hypertension) appeared, lasting 24
hours. Severe agitation and confusion were also present. Restraints and a cumulative dose of 7 mg
lorazepam were used to stabilize her. The confusion resolved in less than 72 hours. The patient
then revealed that she had been using gamma-hydroxybutyric-acid daily for the last six months
as self-medication to treat insomnia and anxiety, before stopping it abruptly 24 hours prior to
her visit.
Conclusions: In our opinion, this original case illustrates the importance of considering gamma-
hydroxybutyric-acid withdrawal delirium in the differential diagnosis of a first-break psychosis. In this
case, the effects of chronic GHB use were incorrectly identified as the negative symptoms of
schizophrenia prodrome. Likewise, severe gamma-hydroxybutyric-acid withdrawal syndrome was
initially mistaken for acute positive symptoms of schizophrenia, until autonomic dysfunction
manifested itself more clearly.
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Gamma-hydroxybutyric-acid (GHB) is a potentially addic-
tive drug used in “rave” parties to heighten sexual drive,
sensuality and emotional warmth. Its euphoric, sedative
and anxiolytic-like properties, and ability to relieve
inhibitions, are also sought by frequent users [1]. Most
of the desired effects are mediated by a direct stimulation
of GABAB receptors and auto receptors in the brain, and
also by its metabolism to GABA in presynaptic neurons.
This pathway is also that of GHB intoxication. The drug’s
addictive properties are mediated by decreased GABA
release in the ventral tegmental area which causes an
inhibition of dopaminergic neurons firing in the nucleus
accumbens and frontal cortex [1]. Regular administration
of GHB causes down regulation of these GABA receptors,
leading to drug dependence as a means to maintain
homeostasis. Abrupt GHB withdrawal will cause imbal-
ance between under-stimulated GABA neurons and
stimulatory input in the ventral tegmental area. This will
cause withdrawal symptoms - tremor, autonomic dysfunc-
tion and anxiety - to appear as soon as one to 24 hrs after
the last dose, resulting in drug craving. Although mild at
presentation, symptoms may culminate in one to seven
days to severe confusion, delirium, auditory, visual or
tactile hallucinations, or even death [2].
Case presentation
We report the case of a 23-year-old French Canadian
woman who presented at the Emergency Room in summer
2006withparanoiddelusionsandauditoryhallucinations.
Her previous history included two brief psychotic episodes
induced by substances (amphetamines and marijuana).
During these previous psychotic episodes, she exhibited
ideas of reference and visual hallucinations which had
responded well to olanzapine, an atypical antipsychotic.
In the last six months, she had shown bizarre behaviour,
had been more isolated and apathetic, and unable to
participate in daily chores. Her motivation had declined.
She had gradually withdrawn from significant social
relationships and stopped working. She described feeling
anxious on a regular basis with no apparent reason. This
was confirmed by family members accompanying her. The
patient reported occasional use of GHB, but as her initial
accounts of drug use were contradictory, the product used
could not be positively identified and frequency of use
remained unknown at the time.
Upon admission, the patient appeared perplexed and
entertained the unsubstantiated fear that someone would
try to kill her. She was under the impression that her whole
entourage was speaking ill of her behind her back. She was
whispering for fear of being heard, and attacked. She
reported not having slept in days. She also mentioned
visual hallucinations, claiming to have seen tigers in her
apartment. The toxicology urine screen was negative. No
evidence of depressive or manic symptoms was found.
Patient history and physical examination indicated no
general medical condition.
The initial suspicion of a schizophrenic disorder was in
accordance with the terms of this diagnosis as described in
theDSM-IV:Thepatientpresentedanacutepsychoticbreak
(hallucinations and delusions, part of Criterion A of the
DSM-IV diagnosis), preceded by a prodrome of negative
symptoms (prolonged apathy and lack of motivation, part
of Criterion A), lasting six months (Criterion C), with a
significant decline in social and occupational functioning
(CriterionB).Mooddisorderswereexcluded(CriterionD).
Substance-inducedandgeneralmedicalcondition-induced
psychoses were excluded as unlikely (Criterion E). The
patient was thus prescribed olanzapine 10 mg at bed time.
Afewhoursafterheradmission,shestartedpresentinglabile
vital signs (Figure 1 and 2): tachycardia (range 160-120
beat/min)andhypertension(range183/95-139/88mmHg)
that lasted for 24 hours. The patient’s temperature was not
taken. She also suffered from severe agitation and anxiety,
showed disorganized speech and behaviour, had insomnia,
and possibly visual hallucinations. Restraints and confine-
menthadtobeusedtoprotectthepatientfrominjury,anda
cumulative dose of 7 mg lorazepam p.o. over 24 hours was
necessary to stabilize her. At this point, we suspected a
withdrawaldelirium,eitherfromethanolorGHBbecauseof
the autonomic system instability. Olanzapine was discon-
tinued(ofwhichshehadreceivedasingledose).Apartfrom
lorazepam, she did not require any further drug treatment.
Her confusion resolved in less than 72 hours. She suffered
from a complete amnesia of the episode.
Figure 1. Patient’s arterial pressure.
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GHB daily for the last six months as a self-medication to
treat insomnia and anxiety. She denied using any other
drug or medication during that time, including alcohol.
She had developed a dependence to GHB as evidenced by
increased anxiety, tremor and insomnia whenever she
skipped a dose, and also by the increasing amount of time
spent seeking and using GHB. She also admitted to often
being very sedated while using GHB, a frequent state
which resulted in a general lack of motivation and interest.
One day prior to her admission, the patient had decided to
put an end to her GHB use, an abrupt interruption which
provoked the onset of intense anxiety and paranoid
delusions within 18 hours, followed by disorganisation,
and auditory and visual hallucinations within 24 hours.
Conclusions
In our opinion, this original case illustrates the importance
of considering GHB withdrawal delirium in the differ-
ential diagnosis of a first break psychosis. In this case,
chronic GHB use was incorrectly perceived as a schizo-
phrenic prodrome characterized mainly by negative
symptoms (Table 1). Likewise, a severe GHB withdrawal
syndrome was initially mistaken for acute positive
symptoms of schizophrenia, i.e. hallucinations and delu-
sions, until autonomic dysfunction manifested itself more
clearly (Table 2).
In a literature search, no other reports of this phenomenon
were found. Since GHB is not usually part of routine
toxicology screens, it is important to consider GHB use
and GHB withdrawal delirium in the differential diagnosis
of psychosis, especially since autonomic dysfunction is
often milder in GHB withdrawal compared to that of
ethanol [3], and since the treatment is different. Obtaining
a detailed history from the patient and family members
and keeping regular track of the vital signs may help make
the proper diagnosis.
The treatment of a GHB withdrawal delirium calls for a
treatment similar that of to ethanol or benzodiazepine
withdrawal, mainly: admission, supportive treatment, and
a tapering regimen of benzodiazepines. Unless a delirium
is present, antipsychotic drugs are not indicated in GHB
withdrawal
3, whereas in schizophrenia, they are the
cornerstone of the treatment.
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Figure 2. Patient’s heart rate.
Table 1. Overlap between negative symptoms of schizophrenia and GHB
chronic use
Symptoms of Chronic
Use of GHB
Negative Symptoms of
Schizophrenia
Lack of volition and drive
Poverty of speech
Loss of feeling
Social withdrawal
Table 2. Overlap between positive symptoms of schizophrenia and GHB
withdrawal delirium
GHB withdrawal delirium Symptoms of Schizophrenia
Disorganized Speech
Disorganized Behavior, Agitation
Delusions
Hallucinations
Autonomic Dysfunction
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